Safety and efficacy of the tumor-selective adenovirus enadenotucirev with or without paclitaxel in platinum-resistant ovarian cancer: a phase 1 clinical trial
Authors
Moreno, V.Barretina-Ginesta, M. P.
García-Donas, J.
Jayson, Gordon C
Roxburgh, P.
Vázquez, R. M.
Michael, A.
Antón-Torres, A.
Brown, R.
Krige, D.
Champion, B.
McNeish, I.
Affiliation
START Madrid-FJD, Hospital Universitario Fundación Jiménez Díaz, Madrid, SpainIssue Date
2021
Metadata
Show full item recordCitation
Moreno V, Barretina-Ginesta M-P, García-Donas J, Jayson GC, Roxburgh P, Vázquez RM, et al. Safety and efficacy of the tumor-selective adenovirus enadenotucirev with or without paclitaxel in platinum-resistant ovarian cancer: a phase 1 clinical trial Vol. 9, Journal for ImmunoTherapy of Cancer. BMJ; 2021. p. e003645.Journal
Journal for Immunotherapy of CancerDOI
10.1136/jitc-2021-003645PubMed ID
34893524Type
Articleae974a485f413a2113503eed53cd6c53
10.1136/jitc-2021-003645
Scopus Count
Collections
Related articles
- A phase 1 dose escalation study of the oncolytic adenovirus enadenotucirev, administered intravenously to patients with epithelial solid tumors (EVOLVE).
- Authors: Machiels JP, Salazar R, Rottey S, Duran I, Dirix L, Geboes K, Wilkinson-Blanc C, Pover G, Alvis S, Champion B, Fisher K, McElwaine-Johnn H, Beadle J, Calvo E
- Issue date: 2019 Jan 28
- A phase 1b study of intraperitoneal oncolytic viral immunotherapy in platinum-resistant or refractory ovarian cancer.
- Authors: Manyam M, Stephens AJ, Kennard JA, LeBlanc J, Ahmad S, Kendrick JE, Holloway RW
- Issue date: 2021 Dec
- Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.
- Authors: Oza AM, Cibula D, Benzaquen AO, Poole C, Mathijssen RH, Sonke GS, Colombo N, Špaček J, Vuylsteke P, Hirte H, Mahner S, Plante M, Schmalfeldt B, Mackay H, Rowbottom J, Lowe ES, Dougherty B, Barrett JC, Friedlander M
- Issue date: 2015 Jan
- Demcizumab combined with paclitaxel for platinum-resistant ovarian, primary peritoneal, and fallopian tube cancer: The SIERRA open-label phase Ib trial.
- Authors: Coleman RL, Handley KF, Burger R, Molin GZD, Stagg R, Sood AK, Moore KN
- Issue date: 2020 May
- Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study.
- Authors: Lakhani NJ, Chow LQM, Gainor JF, LoRusso P, Lee KW, Chung HC, Lee J, Bang YJ, Hodi FS, Kim WS, Santana-Davila R, Fanning P, Squifflet P, Jin F, Kuo TC, Wan HI, Pons J, Randolph SS, Messersmith WA
- Issue date: 2021 Dec